Recombinant Human Thrombopoietin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Recombinant Human Thrombopoietin
DrugBank Accession Number
DB16364
Background

Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.1,2 This drug is used in the treatment of thrombocytopenia.

Type
Biotech
Groups
Investigational
Synonyms
  • rhTPO
  • rHuTPO
External IDs
  • Recombinant Human Thrombopoietin

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Recombinant human thrombopoietin has similar biological functions as endogenous thrombopoietin.2 It activates the thrombopoietin receptor MPL.1 This therapy has potential roles in hematopoietic stem and progenitor cell regeneration and is currently being investigated against relapsed immune thrombocytopenia, hematopoietic injury, and acute severe thrombocytopenia in sepsis.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
E2E529W34D
CAS number
Not Available

References

General References
  1. Wang C, Zhang B, Wang S, Zhang J, Liu Y, Wang J, Fan Z, Lv Y, Zhang X, He L, Chen L, Xia H, Li Y, Pei X: Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation. Sci Rep. 2015 Sep 25;5:12993. doi: 10.1038/srep12993. [Article]
  2. Zhou Z, Feng T, Xie Y, Huang P, Xie H, Tian R, Qian B, Wang R: The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial). BMC Infect Dis. 2019 Sep 6;19(1):780. doi: 10.1186/s12879-019-4388-2. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentThrombocytopenia1
4RecruitingTreatmentPrimary Immune Thrombocytopenia (ITP)1
4RecruitingTreatmentThrombocytopenia1
4Unknown StatusTreatmentAllogeneic Hematopoietic Stem Cell Transplantation (HSCT) / Delayed Platelet Engraftment / Myeloablative1
3CompletedPreventionSarcomas1
3CompletedTreatmentHematologic Diseases / Thrombocytopenia1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura / Pregnant State1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura / Purpura3
3Not Yet RecruitingTreatmentIdiopathic Thrombocytopenic Purpura1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution15000 iu/1ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 17, 2020 22:51 / Updated on May 05, 2021 20:32